News und Analysen

Shares in Pfizer (NYSE: PFE) were falling recently after it discontinued clinical trials for a potential diabetes and weight-loss therapy. The drop was due to negative perceptions after lotiglipron

On June 26, FibroGen's (NASDAQ: FGEN) lead program, pamrevlumab, reported poor late-stage clinical trial results for the second time in a month, sending its stock barreling downward to the tune of

On June 26, Pfizer (NYSE: PFE) gave investors an update that they probably didn't like. One of its two candidates for treating diabetes and obesity, called lotiglipron, will not be developed any

MicroVision (NASDAQ: MVIS) closed the work week in style, with its stock price rising by over 17% on Friday. That was a far better performance than the S&P 500 index's 1.2% increase. Investors

Shares of biosimilar pharmaceutical maker Alvotech (NASDAQ: ALVO) were up more than 11% as of noon on Friday. On Thursday, it plunged more than 6% after the company announced it had received a

Shares of CymaBay Therapeutics (NASDAQ: CBAY) were up more than 37% as of 11:15 a.m. ET on Friday. The clinical-stage biotech saw its shares rise after Ipsen and Genfit announced phase 3 trials data

Things have not quite gone as hoped lately for shares of Sarepta Therapeutics (NASDAQ: SRPT). Recently, the biotech received approval from the Food and Drug Administration (FDA) for its cutting-edge

Shares of Opko Health (NASDAQ: OPK) were up more than 11% around 2:30 p.m. ET on Thursday. The healthcare company announced after the markets closed on Wednesday that a treatment for pediatric

Biotech heavyweight Amgen (NASDAQ: AMGN) will probably continue to be an active player in the merger and acquisition (M&A) scene, regardless of what happens with its proposed $28 billion buyout of

Shares of CorMedix (NASDAQ: CRMD) were down more than 21% as of noon ET on Thursday. The shares fell after the company announced a stock sale. The healthcare stock is down more than 5% so far this

If you're in search of bargain stocks to buy, the healthcare industry is a great place to start looking. The tech sector has been attracting more attention of late due to the hype around artificial

What do CRISPR Therapeutics (NASDAQ: CRSP), Bluebird Bio (NASDAQ: BLUE), Editas Medicine (NASDAQ: EDIT), and Intellia Therapeutics (NASDAQ: NTLA) all have in common? If you said, "They're biotechs

Last year, inflation rose at its fastest pace in over 40 years. The annual inflation rate, as measured by the year-over-year change in the Consumer Price Index (CPI), peaked at 9.1% in July 2022 and

Viking Therapeutics (NASDAQ: VKTX) and Nano-X Imaging (NASDAQ: NNOX) are two small-cap healthcare companies with lots of potential, but their shares come with some hefty risks. They've also both

There's nothing wrong with owning index funds, but growth stocks by definition outpace the revenue or profit of a typical stock, which likely results in greater gains than index funds can produce.

It seems Catalent (NYSE: CTLT) was apparently the reason why a key drug was refused approval by the Food and Drug Administration (FDA).

According to a media report from a leading financial news

Shares of Axsome Therapeutics (NASDAQ: AXSM) were down more than 10% as of 3:45 p.m. ET Wednesday after the company announced it is offering 3 million shares at $75 each in a stock sale worth $225

The stock market has treated investors well so far in 2023, and although the past couple of weeks have been a bit more turbulent, the Nasdaq Composite (NASDAQINDEX: ^IXIC) gave Wall Street a gain of

AbbVie (NYSE: ABBV) is facing a tough year ahead. The company's blockbuster drug Humira, which treats various autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease, will

There are plenty of well-known biotech giants that look like solid investments. But targeting smaller and relatively unknown companies in the industry could provide much juicier returns over the

From June 15 through Monday, shares of Nio (NYSE: NIO) ended each trading session lower than where they had finished the day before. On Tuesday, however, the China-based electric vehicle (EV) maker

Clinical-stage biotech Viking Therapeutics (NASDAQ: VKTX) is having another tough trading session. As of 1:40 p.m. ET Tuesday, Viking's stock was down by 19.8% on higher-than-normal volume

Viking Therapeutics' (NASDAQ: VKTX) shares were down by 9.9% on heavy volume as of 11:14 a.m. ET on Monday. This sizable drop was due to Pfizer's (NYSE: PFE) announcement that it will advance its

Shares of Structure Therapeutics (NASDAQ: GPCR) closed up 18.35% on Monday after the clinical-stage biotech received what is perceived to be good news from Pfizer and a boost from an analyst. The

Amgen (NASDAQ: AMGN) stock came under renewed pressure on Monday, several days after more regulators piled on to block a major acquisition announced by the company. The immediate catalyst was a